In prostate cancer, adiponectin inhibits tumor cell growth by suppressing VEGF-A-mediated tumor neovascularization via AMPK/tuberous sclerosis complex 2 (TSC2), resulting in inhibition of mTOR-mediated VEGF-A activation and decreased VEGF-A production [217]. Here, ADIPOQ is linked to neoplasm.